Life Science Company News

Annual General Meeting 2019 – GN Store Nord A/S

Today, GN Store Nord A/S held its annual general meeting in accordance with the agenda announced on February 27, 2019.

The report by the Board of Directors was adopted, both the Annual Report 2018 and the proposal to distribute dividends of DKK 1.35 per share of nominally DKK 4 were approved, and discharge was granted to the Board of Directors and Executive Management.

The general meeting approved the remuneration to the Board of Directors for 2019.

Per Wold-Olsen, William E. Hoover, Jr., Gitte Pugholm Aabo, Wolfgang Reim, Hélène Barnekow and Ronica Wang were re-elected to the Board of Directors by the general meeting.

Furthermore, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was elected as new auditor for the company.

Moreover, all proposals by the Board of Directors were approved.

At the constituting board meeting held after the annual general meeting, Per Wold-Olsen was elected chairman of the Board of Directors, and William E. Hoover, Jr. was elected deputy chairman of the Board of Directors.

Per Wold-Olsen was also elected as chairman of the remuneration committee and the nomination committee. Gitte Pugholm Aabo was elected as chairman of the audit committee, and Wolfgang Reim was elected as chairman of the strategy committee.

Agenda for the annual general meeting:
a)Report by the Board of Directors on the activities of the company during the past year.
b)Submission of the audited annual report for approval.
c)Resolution of discharge to the Board of Directors and the executive management.
d)Application of profits in accordance with the approved annual report.
e)Approval of remuneration to the Board of Directors for the current financial year.
f)Election of members to the Board of Directors.
g)Election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as new auditor to serve until the company’s next annual general meeting.
h)Proposals from the Board of Directors and shareholders.
h.1Proposals from the Board of Directors.
h.1.1Proposal from the Board of Directors to authorize the Board of Directors to acquire treasury shares up to a total nominal value equivalent to 10% of the share capital, subject to a holding limit of 15% of the share capital, at the market price applicable at the time of purchase subject to a deviation of up to 10%.
h.1.2Proposal from the Board of Directors to reduce the company’s share capital by nominally DKK 13,664,456 by cancellation of treasury shares.
h.1.3Proposal from the Board of Directors to approve a new remuneration policy, including general guidelines for incentive pay.
h.2Proposals from shareholders (None).
i)Any other business.

For further information, please contact:

Investors and analysts
Peter Justesen
VP – Investor Relations & Treasury
Tel: +45 45 75 87 16

Or

Rune Sandager
Senior Manager Investor Relations 
Tel: +45 45 75 92 57


Press and the media
Lars Otto Andersen-Lange
Head of Media Relations & Corporate Public Affairs
Tel: +45 45 75 02 55

About GN Group
The GN Group is a global leader in intelligent audio solutions that let you hear more, do more and be more than you ever thought possible. Our ambitious 150-year journey has taken us from telegraph cables to radio waves and intelligent audio engineering. To celebrate our anniversary, we look to our unique competences within medical, professional and consumer audio solutions to help us continue to transform lives through the power of sound. 

GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra and BlueParrott in 100 countries. Founded in 1869, the GN Group employs 6,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com - and connect with us on LinkedIn, Facebook and Twitter.

Attachment

By: Nasdaq / GlobeNewswire - 21 Mar 2019
Back to overview

Enhance your business development with Biotechgate